STOCK TITAN

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Adaptimmune Therapeutics plc (ADAP) to report financial results and business updates for Q4 and full year 2023, with a live webcast scheduled on March 6, 2024. Investors can access the press release and webcast details on the company's website.
Positive
  • None.
Negative
  • None.

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2023, before the US markets open on Wednesday, March 6, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day.

The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13137. Call in information is as follows: 1-800-319-4610 (US or Canada) or +1-416-915-3239 (International and additional options available HERE). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.

About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2022, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contact

Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
T : +1 215 825 9310
M : +1 215 460 8920
Juli.Miller@adaptimmune.com

Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/198776

FAQ

When will Adaptimmune Therapeutics plc (ADAP) report financial results for Q4 and full year 2023?

Adaptimmune Therapeutics plc (ADAP) will report financial results for the fourth quarter and full year ended December 31, 2023, before the US markets open on Wednesday, March 6, 2024.

How can investors access the press release and live webcast?

Investors can access the press release in the investor section of Adaptimmune's corporate website. The live webcast and replay can be accessed at https://www.gowebcasting.com/13137.

What time is the live webcast scheduled for?

The live webcast by Adaptimmune Therapeutics plc (ADAP) is scheduled for 8:00 a.m. EST (1:00 p.m. GMT) on the same day the financial results are reported.

How can callers join the Adaptimmune call during the webcast?

Callers can dial 1-800-319-4610 (US or Canada) or +1-416-915-3239 (International) 5-10 minutes prior to the scheduled start time and ask to join the Adaptimmune call.

Adaptimmune Therapeutics plc American Depositary Shares

NASDAQ:ADAP

ADAP Rankings

ADAP Latest News

ADAP Stock Data

304.12M
734.09M
0.2%
67.52%
1.3%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
ABINGDON, OXFORDSHIRE

About ADAP

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.